Outcome
Type |
Measure |
Description |
Time frame |
Safety issue |
Other |
Montreal Cognitive Assessment |
The Montreal cognitive assessment will be measured at baseline to determine cognitive status |
Baseline |
|
Other |
Unified Parkinson's Disease Rating Scale Part III |
Part III of the UPDRS is a physical examination that examines the severity of Parkinson's Disease motor symptoms. The UPDRS will be administered at baseline to measure Parkinson's Disease severity |
Baseline |
|
Primary |
% time frozen during a personalized gait trajectory |
The primary outcome measure involves the percentage of time frozen during a personalized walking trajectory that includes self-selected FOG 'hotspots' in the home setting. This gait trajectory will be exactly the same during the baseline and consecutive measurements, and will be performed at comfortable gait speed. The gait trajectory will be video-taped by the assessor and performed three times during each visit. |
Baseline, week after the intervention has ended (5 weeks from baseline) and 10 week follow-up (15 weeks from baseline) |
|
Secondary |
subjective impact of anxiety and stress on FOG, as measured with a Visual Analogue Scale |
subjective impact of anxiety and stress on FOG, as measured with a Visual Analogue Scale |
Baseline, week after the intervention has ended (5 weeks from baseline) and 10 week follow-up (15 weeks from baseline) |
|
Secondary |
Heart Rate Variability |
Heart rate variability (HRV) will be measured to determine whether the gait measures induce physiological stress and to examine if the intervention leads to a reduction in physiological stress. For this purpose, we will collect 3-lead electrocardiogram signals for heart rate monitoring prior to and during the gait measures |
Baseline, week after the intervention has ended (5 weeks from baseline) and 10 week follow-up (15 weeks from baseline) |
|
Secondary |
The Parkinson Anxiety Scale (PAS) |
The Parkinson Anxiety Scale (PAS) [9] is a questionnaire that has been specifically developed for measuring anxiety in people with PD. |
Baseline, week after the intervention has ended (5 weeks from baseline) and 10 week follow-up (15 weeks from baseline) |
|
Secondary |
Gait-Specific Attention Profile |
The Gait-specific attentional profile (G-SAP) provides measurements of multiple psychological factors that influence gait performance. The G-SAP will be administered in order to determine whether psychological factors that are implicated in gait performance (e.g., conscious processing of movement, fall-related ruminations) are changed in response to the intervention |
Baseline, week after the intervention has ended (5 weeks from baseline) and 10 week follow-up (15 weeks from baseline) |
|
Secondary |
he Updated Perceived Control over Falling Scale (UP-COF) |
The Updated Perceived Control over Falling Scale (UP-COF) is a 4-item scale that will be administered to assess whether the intervention improves participants' perceived control over the risk of falling. |
Baseline, week after the intervention has ended (5 weeks from baseline) and 10 week follow-up (15 weeks from baseline) |
|
Secondary |
New Freezing of Gait Questionnaire |
The New-Freezing of Gait Questionnaire (N-FOGQ) assesses the subjective severity of Freezing of Gait. |
Baseline, week after the intervention has ended (5 weeks from baseline) and 10 week follow-up (15 weeks from baseline) |
|
Secondary |
The Parkinson's Disease Questionnaire |
The Parkinson's Disease Questionnaire (PDQ-39) will be administered to measure quality of life. |
Baseline, week after the intervention has ended (5 weeks from baseline) and 10 week follow-up (15 weeks from baseline) |
|
Secondary |
The Rosenberg self-esteem score |
The Rosenberg self-esteem score will be administered in order to assess self-esteem. |
Baseline, week after the intervention has ended (5 weeks from baseline) and 10 week follow-up (15 weeks from baseline) |
|
Secondary |
Perceived Stress Scale |
The Perceived Stress Scale will be administered in order to determine whether the intervention leads to a decrease in perceived levels of stress. |
Baseline, week after the intervention has ended (5 weeks from baseline) and 10 week follow-up (15 weeks from baseline) |
|